Top-line data from CTI Biopharma Corp.'s phase III trial of pacritinib, a JAK2/FLT3 multikinase inhibitor for high-risk patients with advanced myelofibrosis showed the treatment demonstrated statistically significant improvement in spleen volume reduction vs. best available treatment.